Introduction {#cwy053s1}
============

Glycosylation is a common cellular protein modification process whereby carbohydrates (glycans) are attached to specific amino acid side chains in proteins, resulting in glycoproteins (GPs). Cellular glycan functions include protein trafficking and folding, cellular differentiation, receptor binding, cell--cell interactions and cell signaling. Additionally, glycosylation is utilized by many pathogens in host cell invasion and immune system evasion ([@cwy053C230]). Many viruses rely on specific host cell glycosylation patterns for binding to the cell and/or viral entry, as is well documented for both influenza virus and human immunodeficiency virus (HIV) ([@cwy053C169]). Viruses, through their reliance on hijacking host cell machinery for their own reproductive needs, also use host cell machinery to glycosylate their own GPs. These virally encoded, cell-executed GPs have the added benefit of being more likely recognized as "self" proteins by the host immune system, thus helping "hide" the virus from host defenses ([@cwy053C196]; [@cwy053C86]; [@cwy053C18]). Viral GPs then contribute to multiple viral functions, including viral entry and immune evasion ([@cwy053C158]). This has been well characterized in viruses such as HIV, where glycosylation protects the virus from antibody neutralization ([@cwy053C171]; [@cwy053C238]; [@cwy053C196]; [@cwy053C125]), and for influenza virus, where glycosylation modulates virulence and immune system targeting ([@cwy053C172]; [@cwy053C233]; [@cwy053C182]; [@cwy053C217]; [@cwy053C218]; [@cwy053C221]; [@cwy053C222]; [@cwy053C230]; [@cwy053C231]). Functions of glycosylation in other viral systems, however, remain relatively less characterized.

There are two main protein glycan modification types utilized by viruses. The first type, *N*-linked glycosylation, occurs when an *N*-acetylglucosamine (GlcNAc) sugar is covalently attached to an asparagine (N) residue within the predicted sequence N--X--S/T, where N is asparagine, X is any amino acid other than proline and S/T is a serine or threonine residue ([@cwy053C211]). The N--X--S/T motif is necessary but not sufficient for glycosylation, as not all ectodomain N--X--S/T sites are *N*-glycosylated. Factors such as stable conformation adoption, localization of the protein and N--X--ST site accessibility to solvent likely play roles in determining whether a site is *N*-glycosylated ([@cwy053C16]; [@cwy053C262]). *N*-glycans are attached to proteins in the endoplasmic reticulum (ER) early in the protein synthesis process when glycosyltransferases transfer a high-mannose carbohydrate core onto the protein. Further modifications occur as the GP progresses through the ER and the Golgi apparatus as additional carbohydrate residues are added and trimmed. *N*-glycans can be further processed in the Golgi apparatus and identified as high-mannose, hybrid or complex, depending on their carbohydrate content and branching ([@cwy053C169]; [@cwy053C211]; [@cwy053C1]) (Figure [1](#cwy053F1){ref-type="fig"}A).

![Glycosylation schematic. (**A**) Diagram of high-mannose (left), complex (center) and hybrid (right) *N*-glycans. (**B**) Diagram of the four main *O*-glycan core types. (**C**) Differences between *N-* and *O*-glycans.](cwy053f01){#cwy053F1}

The second type of glycosylation, *O*-linked glycosylation, can occur at S or T residues, though most S or T residues are not glycosylated, thus *O*-glycosylation sites are relatively more difficult to predict than *N*-glycosylation sites. *O*-glycans have an *N*-acetylgalactosamine (GalNAc) sugar linked through an *O*-linkage (hence the structural term *O*-glycan) to the free hydroxyl group of the S or T residue ([@cwy053C25]). Additional sugars are then added by numerous glycosyltransferases, resulting in the formation of different core structures, which can then be further modified ([@cwy053C184]). The four most common core structures are shown in Figure [1](#cwy053F1){ref-type="fig"}B. *O*-glycosylation occurs post-translationally in the Golgi apparatus, and unlike *N*-glycosylation, sugar residues are added one by one instead of in a block (Figure [1](#cwy053F1){ref-type="fig"}C). As a result, *O*-glycans tend to be smaller and less branched than *N*-glycans ([@cwy053C224]; [@cwy053C132]; [@cwy053C176]).

Each strategy in the study of glycosylation has advantages and disadvantages. For example, mass spectrometry can yield valuable chemical information but often requires quantities of protein that may be impractical for some viral studies ([@cwy053C180]). Cells can be treated with enzyme inhibitors, such as tunicamycin, a chemical that inhibits *N*-glycan synthesis within the ER, through chemical treatment. However, in addition to blocking glycosylation, tunicamycin may have other undesirable side effects within the cell, such as protein misfolding ([@cwy053C53]). There are also enzymes available for studying glycan composition. Peptide-*N*-glycosidase F (PNGase F) cleaves all *N*-glycans from proteins. Endoglycosidase H (endo H) cleaves high-mannose oligosaccharides and hybrid *N*-glycosylation sites, but not complex *N*-glycans. Endoglycosidase F (endo F) cleaves complex glycans, leaving high-mannose glycans intact ([@cwy053C145]; [@cwy053C211]). Additionally, *O*-glycosidase can remove *O*-glycans ([@cwy053C25]; [@cwy053C141]). Proteins, such as lectins, are additional tools that specifically bind certain types of glycans or antibodies against specific carbohydrates ([@cwy053C180]). Other strategies involve mutating the N--X--S/T sequence via site-directed mutagenesis, usually by mutating the N conservatively to a Q (glutamine), though mutations of N to S (serine), N to A (alanine) or S/T to G (glycine) are published as well ([@cwy053C89]; [@cwy053C263]; [@cwy053C161]; [@cwy053C200]; [@cwy053C3]). An additional strategy is the use of glycosylation-defective cell lines to study glycan effects ([@cwy053C54]). Viruses or viral GPs lacking some or all glycans can then be used for a variety of studies, and results compared to those obtained using fully glycosylated virus or viral GPs. Noteworthy, different cell types have different sets of glycosylation and de-glycosylation enzymes, thus introducing another level of variability to the study of glycan functions ([@cwy053C210]).

The *Mononegavirales* order is comprised of negative-sense single-stranded RNA viruses. This order currently contains eight viral families encompassing 36 genera and over a 100 known species. The families are as follows: *bornaviridae* (e.g. Borna disease virus), *filoviridae* (e.g. Ebola and Marburg viruses), *mymonaviridae* (e.g. sclerotimonavirus), *nyamiviridae* (e.g. nyavirus), *paramyxoviridae* (e.g. measles, mumps and Nipah viruses), *pneumoviridae* (e.g. human respiratory syncytial virus and human metapneumovirus), *rhabdoviridae* (e.g. rabies virus) and *sunviridae* (e.g. Sunshinevirus) ([@cwy053C10]) (Figure [2](#cwy053F2){ref-type="fig"}). Though these viruses have vastly differing hosts and tissue tropisms, they all share a similar genomic organization consisting from 3′ to 5′ ends of core protein genes, envelope GP genes and RNA-dependent RNA polymerase gene ([@cwy053C112]; [@cwy053C177]). Evidently, all *Mononegavirales* virions are enclosed by host cell-derived membrane envelopes ([@cwy053C112]). Here, we summarize the known functions of *N*- and *O*-linked glycans for the *Mononegavirales* and discuss their frequently underestimated importance.

![Diagram of the *Mononegavirales* order. The phylogenetic tree was built after obtaining the RNA polymerase/large protein sequences of the viruses from the NCBI Protein Database. The protein sequences were aligned by using the COBALT Multiple alignment tool, by the fast-minimum evolution method and visualized using Figtree. The virus names and GenBank accession numbers are as follows: *Bornaviridae*---Borna disease virus 1 (BoDV-1; NP_042024), *Filoviridae*---Marburg virus (MARV; YP_001531159), Lloviu virus (LLOV; YP_004928143.1), Zaire ebola virus virus (EBOV; NP_066251.1), *Mymonaviridae*---Sclerotinia sclerotiorum negative-stranded RNA virus 1 (SsNSRV-1; 20996185), *Nyamiviridae*---Nyamanini virus (NYMV; YP_002905337), Pteromalus puparum negative-strand RNA virus 1 (PpNSRV-1; APL97667.1), Soybean cyst nematode virus (SbCNV-1; AEF56729), *Paramyxoviridae*---Avian paramyxovirus 1 (APMV-1; NP_071471), measles virus (MeV; NP_056924), Mumps virus (MuV; NP_054714), Nipah virus (NiV; AAK50546.1), Sendai virus (SeV; NP_056879), Atlantic salmon paramyxovirus (AsaPV; ABX57743.1), Fer-de-Lance virus (FDLV; AAN18266.1), *Pneumoviridae*---human respiratory syncytial virus-A2 (HRSV-A2; NP_056866), Avian metapneumovirus (AMPV; YP_443845), *Rhabdoviridae*---rabies virus (RABV; NP_056797), Tupaia virus (TUPV; YP_238534.1), *Drosophila affinis* sigmavirus (DAffSV; KR822811.1), pike fry rhabdovirus (PFRV; ACP28002.1), Niakha virus (NIAV; AGO44084.1), vesicular stomatitis Indian virus (VSIV; NP_041716), eel virus European X (EVEX; AHD46104.1), bovine ephemeral fever virus (BEFV; NP_065409), Coastal Plains virus (CPV; ADG86364.1), lettuce necrotic yellow virus (LNYV), orchid fleck virus (OFV; NC_009609.1), Datura yellow vein virus (DYVV; AKH61406.1), lettuce big-vein-associated virus (LBVaV; JN710440.1), Arboretum virus (ABTV; AHU86500.1), Flanders virus (FLAV; AAN73288.1), Kumasi rhabdovirus (KRV; YP_009177014.1), Curionopolis virus (CURV; AIE12119.1), infectious hematopoietic necrosis virus (IHNV; NP_042681), *Sunshinevirus*---Sunshine Coast virus (SunCV; YP_009094051.1).](cwy053f02){#cwy053F2}

Bornaviridae {#cwy053s2}
------------

Within the *Bornaviridae* family, there is only the genus Bornavirus, which includes the Borna disease virus (BDV). BDV has been shown to infect a wide range of vertebrates, causing encephalitis and behavioral abnormalities ([@cwy053C136]; [@cwy053C183]; [@cwy053C128]). Although its pathogenicity in humans is controversial, possible links to depression, schizophrenia, multiple sclerosis, chronic fatigue syndrome and aggressive brain tumors have been suggested ([@cwy053C136]; [@cwy053C94]; [@cwy053C128]). Tunicamycin treatment inhibited production of infectious BDV, and glycosidase treatment eliminated virus infectivity, suggesting that glycans play a significant role in BDV pathogenicity ([@cwy053C213]). There are two reported glycosylated BDV proteins. The first is gp18 (or p16), which was initially suggested to be an integral membrane matrix-like GP ([@cwy053C85]; [@cwy053C214]). Gp18 was later proposed to be nonglycosylated and to only line the inner leaflet of the lipid bilayer, as do the typical cytoplasmic matrix proteins of the *Mononegavirales* ([@cwy053C111]). Gp18 is suggested to be essential for infection and includes epitopes important for virus neutralization ([@cwy053C106]; [@cwy053C85]; [@cwy053C214]). Both lectin-binding and endoglycosidase digestion assays have shown the matrix protein to be *N*- but not *O*-glycosylated ([@cwy053C106]). The specific effects of these *N*-glycans in BDV infection and potential neutralization, however, are still unknown. The second glycosylated protein in BDV is the G GP (p56), which is thought to have roles in receptor binding and viral entry. BDV G has been shown to contain *N*-glycans, but no *O*-glycans, and the specific functions of the *N*-glycans remain unknown ([@cwy053C77]; [@cwy053C198]).

Filoviridae {#cwy053s3}
-----------

The filovirus family comprises the *Ebolavirus*, *Marburgvirus* and *Cuevavirus* genera. *Ebolavirus* and *Marburgvirus* infections cause severe hemorrhagic fever with mortality rates of up to 90% ([@cwy053C60]; [@cwy053C147]; [@cwy053C257]). These viruses are classified as bio-safety level 4 pathogens due to their high mortality rates and scarcity of approved treatments or cures. The recent 2014 Ebola outbreak in Africa had \>28,000 infected individuals and \>11,000 deaths, highlighting the need for further study of these deadly viruses ([@cwy053C258]). The filoviruses rely on a single GP for both binding to host cells and viral-cell membrane fusion leading to viral entry ([@cwy053C239]; [@cwy053C92]). GP is cleaved by cathepsins B and L into two subunits linked by a disulfide bond: GP~1~, which binds host cells, and GP~2~, which executes membrane fusion ([@cwy053C31]; [@cwy053C199]; [@cwy053C102]; [@cwy053C239]). There is also a soluble small form of the GP, sGP, whose function is still largely unknown but is suspected to act in immune evasion as a decoy for antibody binding ([@cwy053C185]; [@cwy053C257]).

### Ebolavirus {#cwy053s4}

Ebola virus (EBOV) GP~1~ has four domains: a base, receptor-binding domain, glycan cap domain consisting of only *N*-linked glycan sites and a mucin-like domain (MLD), which is heavily *O*-glycosylated, though it contains N-glycans as well ([@cwy053C62], [@cwy053C61]; [@cwy053C121]; [@cwy053C178]; [@cwy053C122]; [@cwy053C45]). It has been suggested that the thick glycan layer created around GP by the glycan cap and MLD helps in antibody evasion ([@cwy053C121]). In support of this hypothesis, mutation of two *N*-glycosylation sites increased immunogenicity, possibly by unmasking epitopes normally covered by glycans ([@cwy053C50]).

Remarkably, all 15 *N*-glycosylation sites from GP~1~ have been successfully mutated concurrently without affecting GP expression ([@cwy053C122]). *N*-glycan removal did, however, increase protease sensitivity, antibody sensitivity and transduction of pseudotyped virions into cells, suggesting that *N*-glycans protect against proteases and shield against antibody immune responses at the expense of viral entry efficiency ([@cwy053C122]). Single *N*-glycosylation site mutations asparagine to aspartate (N to D), however, were found to have similar processing, expression and transduction levels as wild-type virus ([@cwy053C99]). One mutant, N40D, did display less processing and no transduction. Loss of the same *N*-glycan via a T42D mutation, however, did not result in an altered phenotype, suggesting that the effects observed for the N40D mutant were most likely due to a change in protein conformation (as this site is near a cysteine residue) and not due to loss of the *N*-glycan itself ([@cwy053C99]). Additionally, D is not the most ideal substitution since it introduces a negative charge in addition to the loss of the *N*-glycan. A separate study, however, found T42A or N40K mutants to be cathepsin B resistant, suggesting that the N40 glycan is important for GP cleavage and processing ([@cwy053C245]). Additionally, the amount of *N*-glycan processing can also determine which receptors GP will bind. High-mannose *N-*glycans allow DC-SIGN lectin binding ([@cwy053C127]; [@cwy053C151]; [@cwy053C178]), while the lectin LSECTIN does not recognize high-mannose glycan forms ([@cwy053C78]) and has been shown to bind truncated *N*-glycans ([@cwy053C178]). Thus, *N*-glycans clearly play a role in receptor binding and proper GP cleavage, and these functions may or may not have a direct role in viral entry by modulating receptor-induced membrane fusion.

In comparison to *N*-glycan removal, deletion of the *O*-glycan-rich MLD had more prominent effects. Deletion of the entire MLD resulted in increased processing, incorporation and viral entry using a retroviral system expressing EBOV GP. Deletion of this *O*-glycan-rich region also decreased cellular detachment capabilities, abolished cytopathic effects both in vitro and in vivo and reduced immune responses in mice ([@cwy053C253]; [@cwy053C99]; [@cwy053C205]; [@cwy053C50]). However, since the MLD region is 188 amino acids in length, it is possible that deletion of this region affected the GP conformation ([@cwy053C220]). In virus-like particles (VLPs) studies, immunization of mice with VLPs expressing full-length GP elicited higher antiviral titers than immunization with VLPs expressing an MLD-deleted GP ([@cwy053C150]). Additionally, epitopes of protective monoclonal antibodies (MAbs) were mapped to a domain C-terminal of the GP *O*-glycan-rich region ([@cwy053C241]). The use of two different models, a retroviral system and VLPs, both highly suggest the MLD is important for an immune response, at least in mice, in addition to playing roles in viral infectivity. It should be noted that many of these studies deleted the entire *O*-glycan region, and thus, it remains unclear if the loss of *O*-glycans and/or the loss of the amino acid backbone caused the observed effects. In addition, there are *N*-glycans within the MLD that may partially contribute to the phenotypes observed.

The GP~2~ subunit contains two *N-*glycosylation sites conserved among all five EBOV species ([@cwy053C99]; [@cwy053C185]). Deletion of one of the two *N-*glycosylation sites decreased immunogenicity in mice, possibly by disrupting the dimerization of GP~1~ and GP~2~ ([@cwy053C50]). Interestingly, sGP uses five of its six potential *N-*glycosylation sites and contains no *O*-glycans ([@cwy053C58]; [@cwy053C185]). The sGP *N-*glycans are more processed (containing more complex carbohydrates) than those on GP~1~, but the reasons for these differences in processing are still undetermined ([@cwy053C122]; [@cwy053C185]). Since sGP is suspected to act as an immune system decoy, it would be interesting to investigate whether these sGP *N-*glycans play an immunity role.

### Marburgvirus {#cwy053s5}

Marburg virus contains similar numbers of *N-* and *O*-glycans as an EBOV ([@cwy053C193]). While many of the *N-*glycans on EBOV are complex, Marburg virus contains mainly high-mannose and hybrid *N-*glycans that lack terminal sialic acids ([@cwy053C61]; [@cwy053C71]). The reasons or effects of these differences among these filoviruses, however, have yet to be elucidated, as some of these differences may be a consequence of the different cell lines used to study the different viruses.

### Cuevavirus {#cwy053s6}

Lloviu virus (LLOV) is the first discovered member of the new *Cuevavirus* genus. LLOV was isolated in Cueva de Lloviu, Asturias, Spain after a major die-off of Schreiber's bats ([@cwy053C166]). Similarly to Ebola and Marburg viruses, Lloviu requires NPC1 (an endosomal membrane protein Niemann--Pick disease type C1, used for transport of cholesterol to cellular membranes) to mediate viral entry ([@cwy053C168]; [@cwy053C237]). Vesicular stomatitis virus (VSV)-pseudotyped virions bearing LLOV GP (VSV--LLOV) yielded a transduction efficiency comparable to Ebola and Marburg viruses ([@cwy053C168]; [@cwy053C88]). Sequence analysis of LLOV GP showed it to contain *N-*glycans at both the N-terminus of GP~1~ and C-terminus of GP~2~. Treatment with PNGase F also suggested that LLOV GP~1~ contains a high number of *N-*glycans, similar to Ebola and Marburg viruses. However, the functions of these glycans are unknown ([@cwy053C168]).

### Summary for *Filoviridae* {#cwy053s7}

Both Ebola and Marburg viruses are heavily glycosylated by both *N-* and *O*-glycans, suggesting an extreme importance for these secondary modifications. With less research done on Marburg virus and LLOV, it is difficult to determine if the functions of these glycans demonstrated for EBOV are conserved among the *Filoviridae*. It is interesting to note that the EBOV *N-*glycans do not appear to play important roles in cell surface expression (CSE), a difference from other mononegaviruses such as many paramyxoviruses. However, filovirus *N-*glycans do seem to modulate protease sensitivity and thus protein processing. It appears that the *O*-glycan-rich region is involved more heavily in many of these functions, but since most studies so far deleted this entire region, it remains to be determined whether the *O*-glycans themselves are responsible for the phenotypes observed.

Mymonaviridae {#cwy053s8}
-------------

Sclerotinia sclerotiorum negative-stranded RNA virus 1 (SsNSRV-1) is the only known member of the *Sclerotimonavirus* genus. SsNSRV-1 was isolated in China from a fungal plant pathogen, Sclerotinia sclerotiorum, and has a filamentous viral particle shape. Importantly, to our knowledge, this is the first fungus-infecting mononegavirus discovered. The open reading frames were analyzed and all six proteins were determined to have multiple potential *N-*glycosylation sites, but it is unknown if they are used ([@cwy053C131]).

Nyamiviridae {#cwy053s9}
------------

This family has three genera: *Nyavirus, Socyvirus* and *Peropuvirus*. To our knowledge, no glycan identification or functional studies have been done for any members of the *Nyamiviridae* family.

### Nyavirus {#cwy053s10}

This genus is currently comprised of Nyamanini virus (NYMV), Midway virus (MIDWV) and Sierra Nevada virus (SNVV) ([@cwy053C177]). NYMV and MIDWV viruses are tick-borne and are not known to cause disease in humans or animals, however they can infect birds ([@cwy053C112]). SNVV was isolated after an outbreak of epizootic bovine abortions transmitted by *Ornithodoros coriaceus* ticks in northern California ([@cwy053C189]). Putative glycosylation sites for SNVV have not been described. Both NYMV and MIDWV are predicted to have multiple glycosylation sites on the ORF V. NYMV has one putative *O*-linked and eight potential *N-*linked glycosylation sites in the ORF V (G). The MIDWV ORF V is predicted to have six *N*-linked glycosylation sites on its ORF V (G) ([@cwy053C159]).

### Socyvirus {#cwy053s11}

The soybean cyst nematode virus-1 (SbCNV) belongs to the *Socyvirus* genus and was discovered in the plant parasitic nematode. SbCNV has an ORF IV sequence with one potential *N-*glycosylation site ([@cwy053C2]; [@cwy053C17]).

### Peropuvirus {#cwy053s12}

This is the newest genus to this family, which consists of the Pteromalus puparum negative-strand RNA virus 1 (PpNSRV-1). PpNSRV-1 was found in tissues of the parasitoid wasp, *Pteromalus puparum*, and may be transmitted vertically through infected wasps. The ORF IV protein contains seven putative *O*-linked and four putative *N-*linked glycosylation sites ([@cwy053C236]).

Paramyxoviridae {#cwy053s13}
---------------

The *Paramyxoviridae* family contains many veterinary and medically important viruses such as measles virus (MeV), avian paramyxovirus (APMV-1), parainfluenza viruses (PIV), and the deadly Nipah virus (NiV) and Hendra virus (HeV). These viruses rely on the coordinated efforts of two envelope GPs to enter cells via a viral-cell membrane fusion event (Figure [3](#cwy053F3){ref-type="fig"}A). Additionally, paramyxoviral GP-induced membrane fusion does not require a drop in pH, as many other viral families do. The same two GPs execute cell--cell fusion (syncytia) events (Figure [3](#cwy053F3){ref-type="fig"}B), believed to be a pathway for the virus to spread between host cells without being *intercepted* by the immune system ([@cwy053C32]). Binding of the attachment GP (HN, H or G) to a cell surface receptor triggers the fusion GP (F) to insert itself into the host cell membrane, facilitating viral-cell membrane fusion ([@cwy053C95]; [@cwy053C32]). For F to become biologically active, the precursor (F~0~) is either transported through the *trans*-Golgi network and cleaved by furin, transported to the cellular surface and subsequently endocytosed and cleaved by cellular proteases, or cleaved by extracellular proteases ([@cwy053C32]). This yields the biologically active GP made of F~1~ and F~2~ subunits linked by disulfide bonds. F is then transported to the surface of the plasma membrane ([@cwy053C116]). Here, we discuss the glycan functions by paramyxoviral genus: *Aquaparamyxovirus*, *Avulavirus*, *Ferlavirus*, *Henipavirus*, *Morbillivirus*, *Respirovirus* and *Rubulavirus*.

![Diagram of the viral life cycle. (**A**) Virions bind to host cell receptors (black), facilitating viral entry into the cell. Once within the cell, transcription and replication occur. This allows the production of viral proteins, which are processed and trafficked through the cell using host cell machinery (endoplasmic reticulum and Golgi apparatus). Viral proteins and RNA are packaged into new virions, which are then released from the cell. These virions can then interact with the host immune system. (**B**) Infected cells can express viral proteins on their cell membranes, which can react with cell receptors on neighboring naïve cells, causing cell--cell fusion.](cwy053f03){#cwy053F3}

### Aquaparamyxovirus {#cwy053s14}

The *Aquaparamyxovirus* genus is currently solely comprised of the Atlantic salmon paramyxovirus (AsaPV). Upon infection, inflammation of the gills and respiratory distress were followed with an accrued mortality of 40% in farmed Atlantic salmon ([@cwy053C115]). The AsaPV F has two putative *N-*glycosylation sites, one at the F~1~ subunit one at the F~2~ subunit, and the HN protein has four potential *N-*glycosylation sites, all with unknown functions ([@cwy053C57]).

### Avulavirus {#cwy053s15}

Newcastle disease virus infects avian species and is endemic in many third-world countries. It is designated as serotype-1 of the APMV-1. APMV-1 causes severe economic losses for many poultry farmers due to its high morbidity, mortality and its infectious nature ([@cwy053C67]). Studies in Lec1 cells, a cell line lacking the enzymes necessary to convert high-mannose *N-*glycans to complex or hybrid forms, suggest that APMV-1 fusion and infection are not dependent on hybrid or complex *N-*glycans. This suggests that high-mannose *N-*glycans may play a role in cell--cell fusion, however, the folding of these GPs was not studied ([@cwy053C215]).

APMV-1F contains four *N-*glycosylated sites. Mutation of these sites altered F processing and decreased cell--cell fusion ([@cwy053C156]). In contrast, the removal of *N-*glycans specifically from the heptad repeat regions 1 and 2 of APMV-1F in combination resulted in increased virulence and immunogenicity of virions ([@cwy053C192]), suggesting that the effects of *N-*glycans on APMV-1F may be location-specific. Interestingly, the latter study also found that the removal of *N-*glycans did not affect APMV-1F processing or CSE, conflicting with the previously mentioned study. These differences may be due to the use of transfected vs. infected cells or the use of S/T to A mutations in the first study vs. N to Q mutations in the second.

APMV-1 HN utilizes four of its six potential *N-*glycosylation sites, two of which modulate protein folding and activity ([@cwy053C154]). N to Q mutations caused altered fusion activity (usually lower, but one double mutant had increased fusogenicity), and all were less virulent ([@cwy053C174]), an interesting result since fusogenicity often directly correlates with virulence. The N481 mutant had lowered CSE, suggesting that the most C-terminal *N-*glycan is important for processing and/or transport. None of the mutants had altered cell receptor-binding abilities, though two had decreased neuraminidase activities, suggesting that the decreased virulence of these mutants may be due, at least partially, to a decreased cellular detachment ability ([@cwy053C174]). Furthermore, it has been shown that failure to form a disulfide bond results in an additional *N-*glycosylation, possibly by causing differential folding that exposes an otherwise obscured site to glycosyltransferases ([@cwy053C155]). However, when a D287N mutation introduced an *N-*glycan the effect of neutralizing antibodies was reduced. Interestingly, the D287N mutation also reduced fusion from within (fusion induced by infected cells) and increased fusion from without (cell--cell fusion mediated by virus at a high multiplicity of infection). Overall, addition of the *N-*glycan caused diminished syncytium formation as compared to wild-type HN and enabled the virus to escape from neutralizing MAbs specific for antigenic site 3 ([@cwy053C46]). The effects of this additional glycosylation on virulence and pathogenicity, however, are still somewhat unclear.

### Ferlavirus {#cwy053s16}

The Fer-de-Lance virus (FDLV) was isolated after an outbreak in a Swiss serpentarium that caused lethargy, respiratory distress, and death ([@cwy053C37]). FDLV may cause epidemics in captive reptile populations with high mortality rates ([@cwy053C63]). The FDLV HN GP has two putative *N-*linked glycosylation sites. As for the FDLV F GP, it has three putative *N-*linked glycosylation sites, two within the F~1~ subunit and one in F~2~ ([@cwy053C113]). No further studies on the role of glycans in the virus life cycle have been conducted.

### Henipavirus {#cwy053s17}

The *Henipavirus* genus contains the deadly emerging zoonotic NiV and HeV, as well as Cedar, Mojiang, Kumasi, and over a dozen new uncharacterized and unnamed henipaviruses recently discovered in bats ([@cwy053C51]; [@cwy053C148]; [@cwy053C246]). All glycobiology studies so far have focused on NiV and HeV. Infection with NiV or HeV results in severe respiratory and neurological symptoms in humans, progressing to fatal encephalitis in 40--100% of cases ([@cwy053C135]). Both viruses are bio-safety level 4 pathogens, with no currently approved treatment or vaccine available for human use.

NiV F is glycosylated at four of its five potential *N-*glycosylation sites ([@cwy053C161]; [@cwy053C5]). Loss of some of the *N-*glycans by N to Q mutations resulted in increased fusogenicity but also increased susceptibility to antibody neutralization, implying a need for NiV to balance these two important glycan functions, and one *N-*glycan was relatively more important for protein expression/transport ([@cwy053C5]). The same *N-*glycosylation sites are used in HeV F, and similarly, of these, the equivalent *N-*glycan as for NiV (N414 in HeV) is important for proper folding and transport, while the removal of the N464 *N-*glycan yielded an increase in fusion, the other two had no significant effect on fusion ([@cwy053C28]), an interesting difference from NiV. Additionally, Galectin-1, a lectin that binds primarily a specific *N-*glycan in NiV F, inhibited NiV cell--cell fusion if added post-infection but enhanced viral entry if present at the time of infection by increasing viral attachment to target cells ([@cwy053C69], [@cwy053C70]; [@cwy053C124]), demonstrating the importance of the timing of viral exposure to this innate immune factor.

Six of seven potential NiV G *N-*glycosylation sites are utilized: one in the stalk and five in the globular head domain. The removal of *N-*glycans from the head region of NiV G generally resulted in increased fusion, with some synergistic effects observed for double or triple mutants, which had higher fusion levels than their individual site counterparts. These mutants were also more susceptible to antibody neutralization, similar to NiV F *N-*glycans. In contrast, the removal of an *N-*glycan in the NiV G stalk created a fusion-dead mutant, even in combination with the removal of *N-*glycans from sites that created hyperfusogenic mutants when removed on their own. NiV G *N*-glycan removal also affected viral entry and binding avidities with NiV F, though protein conformations and receptor-binding capabilities were not significantly affected ([@cwy053C18]). The removal of *N*-glycans from HeV G revealed similar trends. However, simultaneous removal of multiple *N*-glycans from HeV resulted in a much stronger reduction in CSE than from NiV. Additionally, the removal of the N306 and N378 *N*-glycans from HeV G resulted in higher cell--cell fusion levels than for NiV, while the removal of the N481 and N529 *N*-glycans of NiV caused higher fusion levels than for HeV ([@cwy053C24]). These differences suggest conformational or functional differences for the same *N*-glycans in the two closely related viruses and/or differences in glycan branching/composition. Mass spectrometry analysis of a soluble HeV G showed it contained mainly complex *N*-glycans ([@cwy053C38]), but a similar mass spectrometry analysis has not been performed for NiV G.

Interestingly, the loss of *N*-glycans for NiV and HeV not only correlated to an enhancement of membrane fusion but also to looser F/G GP--GP interactions. This phenotype illustrates that not only the inherent fusogenic capacities of the GPs, but also their interactions important for their membrane fusion functions can be modulated by *N*-glycans. These results have also helped to confirm the F/G dissociation model of membrane fusion for this *paramyxovirus* genus ([@cwy053C3]; [@cwy053C4]; [@cwy053C24]).

*Relatively little is known about the functions of O-glycans for the Mononegavirales, and no function had been described for any paramyxoviral O-glycan until a recent study* by [@cwy053C212]. HeV G has been shown to contain *O*-glycans via mass spectrometry ([@cwy053C38]). Loss of specific *O*-glycosylation sites from the HeV G stalk affected cell--cell fusion, protein conformational changes, binding avidities with HeV F, pseudotyped viral entry, and quite interestingly, HeV F protein processing and incorporation into pseudotyped virions ([@cwy053C212]). Since F and G are thought not to interact until reaching the cell surface, it is quite interesting that loss of an *O*-glycan on G affects F incorporation into virions, especially since this effect was observed in pseudotyped virions but not in cell lysates. Similar effects were observed for the same *O*-glycan mutants in NiV G, with the exception that interestingly, NiV F incorporation into pseudotyped virions and pseudotyped viral entry were not altered by the loss of *O*-glycans on NiV G. Additionally, one mutant in NiV G was unable to express at the cell surface even though its HeV G counterpart expressed at wild-type G levels ([@cwy053C212]). Loss of an *O*-glycan in either HeV or NiV G had no effect on antibody neutralization susceptibility, demonstrating functional differences between *N*- and *O*-glycans for the Henipaviruses. Additionally, *O*-glycans were shown not to affect G oligomerization. All these results suggest the importance of both *N*- and *O*-glycans in the henipavirus life cycle, though there appears to be subtle differences of their effects between NiV and HeV.

### Morbillivirus {#cwy053s18}

The *morbillivirus* genus contains important viruses such as MeV and canine distemper virus (CDV). Measles infections represent one of the largest causes of childhood morbidity and mortality. In addition to acute infection, characterized by the development of a skin rash, there is a risk of developing subacute sclerosing panencephalitis, an often fatal neurological disease resulting from persistent MeV infection ([@cwy053C79]). CDV causes symptoms such as fever, respiratory distress and neurological disorders and infects dogs and many other carnivore species ([@cwy053C83]; [@cwy053C149]).

*N*-glycans on both MeV F and MeV H are important for syncytia formation ([@cwy053C146]), and the specific processing of these *N*-glycans is crucial. Treatment with an α-glucosidase inhibitor, castanospermine, revealed that trimming of glucose residues within the ER was required for syncytia formation and for infectivity ([@cwy053C146]; [@cwy053C21]). Additionally, tunicamycin treatment to block *N*-glycan synthesis inhibited virion particle formation ([@cwy053C209]). All three potential MeV F *N*-glycosylation sites are glycosylated and *N*-glycan removal from any resulted in loss of protein CSE and/or processing ([@cwy053C7]; [@cwy053C232]). Nonconservative mutations (N to S) of N29 and/or N61 resulted in a lack of MeV F processing and transport to the cell surface ([@cwy053C89]). Results were similar for conservative mutations (N to Q), as *N*-glycan loss resulted in reduced MeV F CSE ([@cwy053C7]). Interestingly, mutant N61Q still had fusion activity, while mutant N29Q did not, a finding differing from the N to S mutations where neither mutant was fusogenic, suggesting that the loss of fusion for mutant N61S was due to the loss of the N residue and not the glycan. Mutation N67Q alone did not affect protein processing or fusogenicity but combined with the loss of either of the other two glycans resulted in impaired cleavage, stability, CSE, processing and fusion ([@cwy053C7]). These results highlight the importance and partial flexibility of *N*-glycans on MeV F for proper protein processing, expression and function.

MeV H is glycosylated at four out of five potential *N*-glycosylation sites ([@cwy053C21]). Two of the four *N*-glycans affect GP conformation, as measured by conformational MAbs. No individual *N*-glycan affected folding, oligomerization or transport, but the presence of at least two of the four *N*-glycans were necessary for these functions, suggesting transport and folding are not dependent on a specific carbohydrate chain but do rely on a collective carbohydrate functions ([@cwy053C90]). Crystallization data suggest that *N*-glycans may modulate receptor binding by positioning MeV H for receptor binding ([@cwy053C84]). Supporting this notion, MeV H binding to the CD46 receptor was shown to be dependent on *N*-glycans, but not *O*-glycans, on MeV H, suggesting that *N*-glycans help keep MeV H in a conformation recognized by CD46. Likewise, the CD46 receptor also requires *N*-glycans to serve as the receptor for MeV H ([@cwy053C144], [@cwy053C142]; [@cwy053C143]). However, it has been argued that CD46 is not a relevant in vivo receptor ([@cwy053C170]), thus the biological significance of these findings remains to be determined. The effects of glycosylation on MeV H interactions with signaling lymphocyte activation molecule (SLAM) or Nectin 4, the two other known and biologically relevant receptors of MeV, have not been reported. Regardless, *N*-glycans on MeV H appear to play a general role in keeping MeV H in a favorable functional conformation.

Similar to MeV F, N to Q mutations demonstrated that CDV F also uses all three potential *N*-glycosylation sites, and these *N*-glycans are important for processing, protein stability, CSE and fusion ([@cwy053C232]). CDV H contains three *N*-glycosylated sites conserved among all CDV strains, with up to an additional five sites present in some wild-type strains. Loss of all *N*-glycosylation sites from CDV H using N to Q mutations resulted in a functional and immunosuppressive CDV H GP, but one that no longer caused disease ([@cwy053C195]). It has also been suggested that lack of *N*-glycans on the attenuated vaccine strain may be responsible for the loss of virulence ([@cwy053C96]). These results support the importance of *N*-glycans in GP function, pathogenicity and vaccine development. Notably, *N*-glycan presence appears to be more conserved between *Morbillivirus* F GPs (three out of three sites for both MeV and CDV, all in conserved positions) than between the H GPs (four out of five on MeV, and up to eight on CDV), suggesting that H is under higher host immune pressure.

### Respirovirus {#cwy053s19}

Human parainfluenza virus (HPIV) types 1--3 are major causes of respiratory tract infections in children, the elderly and immunocompromised individuals ([@cwy053C160]; [@cwy053C36]; [@cwy053C14]). Sendai virus (SeV) is a murine virus that has functioned as a model virus in many paramyxoviral studies ([@cwy053C177]).

The HN GP of HPIV-3 utilizes three of its four potential *N*-glycosylation sites. Mutation (N to A) of these sites revealed that *N*-glycans on HPIV-3 HN are important for receptor binding, *F* cleavage, fusion, but not in HN avidity for HPIV-3F or neuraminidase activity ([@cwy053C36]). Remarkably, *N*-glycan loss from HPIV-3 HN affected F cleavage without affecting overall interactions with HPIV-3F, findings that warrant further investigation and suggest the roles of unknown factors involved. Additionally, the *N*-glycan at HPIV-3 HN N523 was found to cover a second receptor-binding site ([@cwy053C160]). A similar observation was seen for HPIV-1 HN residue N173 ([@cwy053C9]), though the implications of these additional binding sites on viral infectivity have yet to be defined.

Similar to HPIV-3, SeV HN utilizes three of its four potential *N*-glycosylation sites, and 9% of its mass can be attributed to glycan modifications ([@cwy053C107]; [@cwy053C201]). These *N*-glycans play a significant role in intracellular transport and fusion ([@cwy053C201]). Fifteen percent of the mass of SeV F is attributable to *O*-glycan modifications ([@cwy053C107]), and SeV F has three *N*-glycosylation sites. The removal of the N245 site affected protein folding, trafficking, CSE, and, as a result, fusion ([@cwy053C202]). High-mannose sugars are thought to be necessary for the immunoreactivity of SeV F, but not SeV HN ([@cwy053C163]). Additionally, tunicamycin treatment inhibited SeV viral replication ([@cwy053C164]). Thus, it is clear that *N*-glycans play a significant role in protein processing, proper viral function for these viruses, and that targeting these glycans may be a potential therapeutic option.

### Rubulavirus {#cwy053s20}

Parainfluenza virus 5 (PIV-5) has a broad host range including cats, dogs, pigs, guinea pigs and hamsters, and PIVs can cause hospitalizations in humans ([@cwy053C34]). PIV-5 F utilizes all six potential *N*-glycosylation sites. The removal of the two F~2~ subunit *N*-glycans via N to A mutations had no significant effects. However, the removal of any of the four F~1~ subunit *N*-glycans resulted in protein degradation, instability and delayed intracellular transport, CSE and fusion ([@cwy053C13]). PIV-5 HN contains four *N*-glycans that affect protein folding and assembly in a cumulative manner. Additionally, one of these four *N*-glycans prevents aggregation of oligomers in the ER ([@cwy053C167]). Thus, *N*-glycans on both PIV-5 F and HN play roles in proper protein folding, thus facilitating proper viral protein function.

Mumps virus (MuV) causes painful swelling of the salivary gland as well as the potential for systemic inflammation in organs including the brain, heart and kidneys. Though rarely fatal, in some cases infection can result in long-term symptoms such as paralysis, seizures and deafness. Before the introduction of a vaccine, mumps was a common childhood infection ([@cwy053C191]). Tunicamycin treatment inhibits viral release, likely by trapping viral GPs in the cytoplasm of the infected cell. Both the HN and F GPs are *N*-glycosylated with both complex and high-mannose glycans (HN and F~1~ subunit) or only high mannose (F~2~ subunit), as revealed by endoglycosidase treatments ([@cwy053C87]). MuV F contains six potential *N*-glycosylation sites ([@cwy053C6]), while MuV HN contains five to seven potential *N*-glycosylation sites ([@cwy053C126]; [@cwy053C254]), though site utilization and functions remain unknown. It is thus unknown whether the *N*-glycan functions among rubulaviruses are conserved.

### Summary for *Paramyxoviridae* {#cwy053s21}

While the paramyxoviruses vary extensively in host range and distribution, they share many similarities within their GPs. Both the F and HN/H/G GPs for each virus within this family contain a number of *N*-glycans, though the number of *N*-glycosylation sites utilized varies widely among genera. *N*-glycans commonly appear to have roles in protein expression, processing, trafficking to the cell surface, cell--cell fusion and production of infectious virions. Additionally, many *N*-glycans also affect pathogenicity and immunogenicity. Some, such as the glycans on HPIV3 HN, affect receptor binding, while others have no effect on receptor binding at all but affect cellular detachment. Additionally, *O*-glycans have been detected on some paramyxoviral GPs, and their functions so far have only been determined for NiV and HeV G GPs. Research will determine if these *O*-glycan functions are conserved among the paramyxoviral genera.

Pneumoviridae {#cwy053s22}
-------------

### Orthopneumovirus {#cwy053s23}

Human respiratory syncytial virus (HRSV, also referred to as RSV) causes severe bronchiolitis in infants, accounting for over 50% of childhood bronchiolitis cases requiring hospitalization ([@cwy053C188]). It is estimated that most children will have at least one HRSV infection by the age of 2 ([@cwy053C22]). Interestingly, for HRSV, only the fusion GP is required for cell--cell fusion and viral entry to occur, though the presence of HRSV G enhances fusion ([@cwy053C32]). HRSV infectivity is sensitive to *N-* or *O*-glycan removal ([@cwy053C117]). HRSV F utilizes three of its six potential *N*-glycosylation sites. The removal of these *N*-glycans through conservative N to Q mutations did not affect HRSV F expression or processing (cleavage activation). However, one mutant, N70Q, had a 40% increase in fusion, while another mutant, N500Q, had a 90% fusion reduction. A mutant lacking all three *N*-glycosylation sites had almost no fusion ([@cwy053C263]). Since conformations of these proteins were not tested, it is possible that the altered fusion phenotypes were due to altered protein conformations. Conformational MAbs may help determine if this is the case. Importantly, it is still unknown whether HRSV F glycans affect the binding of HRSV F to palivizumab, a therapeutic MAb against HRSV and to our knowledge still the only MAb approved for use in humans against any virus.

HRSV G has been shown to be heavily *O*-glycosylated, with only 3% of its mass from *N*-glycans but 55% from *O*-glycans based on gel motility ([@cwy053C117]). Interestingly, certain MAbs did not bind nonglycosylated G ([@cwy053C173]), and the recognition of some MAbs depended on cell-specific glycosylation ([@cwy053C68]). *O*-glycans have been shown not to be involved in HRSV G oligomerization ([@cwy053C39]). Additionally, modeling studies suggest a positive selection of certain *O*-glycans in response to immune pressure ([@cwy053C264]), suggesting that viral glycosylation may play an important role in the host immune response. Further study of immune responses to glycosylation may lead to more effective vaccines or therapeutic options.

### Metapneumovirus {#cwy053s24}

As with HRSV, human metapneumovirus (HMPV) causes severe upper and lower respiratory tract infections and accounts for 5--10% of childhood acute respiratory infection hospitalizations ([@cwy053C175]). Infection generally occurs during childhood, but can be recurrent throughout life. In addition to infecting children, HMPV also poses a threat to immunocompromised individuals, including the elderly ([@cwy053C175]). HMPV F utilizes all three potential *N*-glycosylation sites: one on the F~2~ and two on the F~1~ subunits. N to A mutations resulted in decreased cell--cell fusion, most likely caused by reduced F cleavage, and all mutants expressed well at the cell surface ([@cwy053C200]). In another study, mutants lacking the most C-terminal *N*-glycan, N353, either alone or in combination with the removal of other *N*-glycosylation sites did not produce virions ([@cwy053C259]). Although N to Q vs. N to A mutations as well as virus vs. transfected cells were significant differences between these two studies, it appears that *N*-glycans on HMPV F affect cleavage of F into its F~1~ and F~2~ subunits, impacting viral replication and cell--cell fusion ([@cwy053C200]; [@cwy053C259]). Viruses lacking the N172 glycan displayed impaired growth in vitro and in vivo and reduced pathology in both immunocompetent and immunocompromised mice ([@cwy053C259]; [@cwy053C256]). Administration of a live vaccine attenuated by the loss of the N172 glycan resulted in immune protection in mice ([@cwy053C130]), highlighting the ways in which knowledge of viral glycosylation can aid viral infection prevention strategies.

Like HRSV G, HMPV G is heavily glycosylated, with three to six potential *N*-glycosylation sites depending on the strain, and an unknown number of *O*-glycans ([@cwy053C15]; [@cwy053C65]; [@cwy053C129]). Sequencing of HMPV G strains, however, has revealed a high serine and threonine content of 30--34%, suggesting that HMPV G may have a high *O*-glycan content ([@cwy053C129]). Effects of the actual or putative *N*- or *O*-glycans are still largely undetermined.

### Summary for *Pneumoviridae* {#cwy053s25}

Members of this family have been observed to undergo attachment protein-independent membrane fusion ([@cwy053C95]; [@cwy053C207]). There is extensive *O*-linked as well as *N*-linked glycosylation of the G GP ([@cwy053C235]). This, along with high proline content, suggests the G GP has a mucin-like structure ([@cwy053C101]; [@cwy053C118]). Though the functions of *Pneumoviridae* fusion GP *N*-glycans have been characterized, the purpose of G GP *N*- and *O*-glycans remains unknown.

Rhabdoviridae {#cwy053s26}
-------------

The widely distributed rhabdoviruses infect both invertebrates and vertebrates, as well as a wide variety of plants. They have been divided into 18 genera. Four of these genera infect mammals: *Lyssavirus*, containing rabies virus (RABV), *Tibrovirus, Vesiculovirus*, containing VSV, and *Ephemerovirus*, containing bovine ephemeral fever virus (BEFV), and the *Tupavirus* infects birds ([@cwy053C43]; [@cwy053C27]). Three genera that infect fish include *Novirhabdoviruses, Perhabdoviruses* and *Spriviviruses*. The *Cytorhabdoviruses*, *Nucleorhabdoviruses*, *Dichorhaviruses* and *Varicosaviruses* infect plants ([@cwy053C58]). Members of the *Almendravirus, Sigmavirus, Ledantevirus, Peropuvirus* and *Hapavirus* genera circulate within arthropod populations ([@cwy053C40]; [@cwy053C20]; [@cwy053C41]; [@cwy053C236]). These viruses all have a bullet-shaped morphology and enter cells through receptor-mediated endocytosis followed by membrane fusion induced by low pH. Both host cell receptor binding and membrane fusion are executed by the envelope GP G, which for the two most widely studied viruses from this family, RABV and VSV, contains two *N*-glycosylation sites ([@cwy053C98]; [@cwy053C43]).

### Almendravirus {#cwy053s27}

Members of the *Almendravirus* genus were isolated from mosquitoes and found to effectively replicate in mosquito cells ([@cwy053C41]). The Arboretum virus (ABTV) and Puerto Almendras virus (PTAMV) are suggested to have six putative *N*-glycosylation sites within its G ORF ectodomain ([@cwy053C228]). The Balsa virus (BALV) and Rio Chico virus (RCHV) have two putative *N*-glycosylation sites, while Coot Bay virus (CBV) contains five ([@cwy053C41]). The role of these putative *N*-glycans have not been determined.

### Curiovirus {#cwy053s28}

Members of the *curiovirus* genus have been reported to be lethal in mice, causing necrosis and pyknosis. The Curionopolis, Ibirius and Itacainus viruses were isolated in Brazil from species of Culicoides insects, causing neuropathogenesis in mice ([@cwy053C76]; [@cwy053C48]). No characterization of the *curiovirus* GPs has been conducted.

### Cytorhabdovirus and Nucleorhabdovirus {#cwy053s29}

The plant rhabdoviruses can be separated into the *cytorhabdovirus* and *nucleorhabdovirus* genera depending on their sites of replication and morphogenesis ([@cwy053C97]). The number of potential *N*-glycosylation sites for these viruses varies widely. The *cytorhabdovirus* lettuce necrotic yellow virus (LNYV) G contains three potential *N*-glycosylation sites, while the Northern cereal mosaic virus (NCMV) contains six ([@cwy053C75]; [@cwy053C216]; [@cwy053C97]; [@cwy053C47]). The *nucleorhabdoviruses* rice yellow stunt virus (RYSV) and sonchus yellow net virus (SYNV) contain 10 and 6 potential *N*-glycosylation sites, respectively ([@cwy053C97]). Tunicamycin treatment suggests that at least some of these *N*-glycosylation sites are used ([@cwy053C97]). Interestingly, there is very little sequence homology between NCMV and SYNV G, yet they are both potentially glycosylated at similar sites, suggesting the importance of glycosylation site conservation ([@cwy053C216]). The functions of these *N*-glycans, however, have yet to be determined.

### Dichorhavirus {#cwy053s30}

The *Dichoraviruses*, which include the coffee ringspot virus (CoRSV) and orchid fleck virus (OFV) (synonymous with the citrus leprosis virus nuclear type and citrus necrotic spot virus), cause necrotic symptoms in plant species spread by the *Brevipalpus* species of mites. The OFV G protein has two potential *N*-glycosylation sites, and interestingly it has been proposed that the fewer potential *N*-glycans may contribute to the incomplete budding process of the virions ([@cwy053C108], [@cwy053C109]).

### Ephemerovirus {#cwy053s31}

BEFV infections occur mainly in cattle and buffalo in Africa, Asia and Australia, causing acute fever and lameness, resulting in high morbidity and economic loss. BEFV can also infect other ruminants without causing disease ([@cwy053C165]). BEFV G contains five potential *N*-glycosylation sites. Additionally, a nonstructural protein with 36% similarity to G, termed G~ns~, contains eight potential *N*-glycosylation sites ([@cwy053C100]). G~ns~ is detected within infected cells; however, it is not found in virions and does not appear to induce an immune response. The utilization of the potential *N*-glycosylation sites and the glycan functions are still unknown ([@cwy053C234]; [@cwy053C100]).

### Hapavirus {#cwy053s32}

Several viruses of this new genus can infect mammals, birds, insects or reptiles, though most were isolated from mosquitoes ([@cwy053C30]; [@cwy053C103]; [@cwy053C206]). Ngaingan virus (NGAV) was first isolated from biting midges in Australia and is predicted to have four *N*-glycosylation sites on its NGAV G ([@cwy053C49]; [@cwy053C82]). The Marco virus was isolated from lizards in Brazil and has two putative *N*-linked glycosylation sites on its transmembrane GP ([@cwy053C30]; [@cwy053C5135]). No glycan functions have been studied for any of the 15 *Hapavirus* species.

### Ledantevirus {#cwy053s33}

Within the *Ledantevirus* genus, the Kolente virus has four putative *N*-glycosylation sites with unexplored functions within the GP ([@cwy053C72]).

### Lyssavirus {#cwy053s34}

RABV infects most mammals and is transmitted through bites, scratches and saliva. Infection is characterized by neurological symptoms culminating in severe encephalitis and is fatal in humans if untreated ([@cwy053C27]). RABV G usually contains one (N319) *N*-glycosylation site highly conserved among different RABV strains ([@cwy053C247], [@cwy053C248]; [@cwy053C12]; [@cwy053C252]). Additionally, an *N*-glycan at site N247 is found in many lab-adapted strains ([@cwy053C247]). It has been suggested that the latter *N*-glycan may play a role in the reduced pathogenicity observed in many of these lab-adapted strains and possibly the increased efficiency for growth in cell culture ([@cwy053C252], [@cwy053C249]). Further, N37 is inefficiently glycosylated and efforts to increase *N*-glycosylation efficiency reduced pathogenicity of the virus ([@cwy053C247]; [@cwy053C203], [@cwy053C204]; [@cwy053C250]). Loss of the *N*-glycan at N319 resulted in decreased viral production and an inability for RABV G to fold correctly that inhibited membrane fusion ([@cwy053C251]). Deletion of all three *N*-glycans completely blocked CSE. A mutant containing only the N37 glycan was still able to express on the cell surface, suggesting that this inefficiently glycosylated site is not important for CSE ([@cwy053C203]). Addition of an extra *N*-glycan (N194), created from spontaneous mutation during serial passage, increased virus production ([@cwy053C251]). Thus, it appears that *N*-glycans play a crucial role in proper RABV G CSE, though the combined effects of glycans at all the *N*-glycan sites suggest a crucial balance where too few or too many *N*-glycans negatively impact viral pathogenicity.

Tunicamycin treatment blocked CSE of RABV G but not intracellular synthesis ([@cwy053C26]; [@cwy053C243]). Additionally, experiments with a panel of various CHO cell lines deficient for different steps in the *N*-glycan processing pathway revealed that RABV G expression was independent of the type of *N*-glycan processing, as all cell lines expressed RABV G on the cell surface ([@cwy053C26]). It is still possible that RABV G trafficked at different rates, as the timing of RABV G CSE was not explored. Notably, mutation of site N247 facilitated an additional glycosylation of site N319 ([@cwy053C244]). Recombinant RABV G protein produced in eukaryotic cells (and thus glycosylated) was effective as a vaccine ([@cwy053C104]; [@cwy053C240]), while RABV G protein produced in prokaryotic cells (and thus not glycosylated) was not effective ([@cwy053C255]). While these differences could be due to other factors such as protein conformation, it is possible that proper glycosylation of RABV G is necessary for effective immune responses. However, another study indicated that glycans may not be a required target for mouse antibodies ([@cwy053C247]), suggesting that the immunoreactivity of RABV G is multifactorial. Undoubtedly, *N*-glycans play a critical role in at least proper CSE of RABV G, though their effects on the host immune response merit further exploration.

### Novirhabdovirus {#cwy053s35}

Viruses within the *Novirhabdovirus* genus infect fish species, causing significant morbidity and mortality. These viruses include infectious hematopoietic necrosis virus (IHNV), hirame rhabdovirus (HIRV) and viral hemorrhagic septicemia virus (VHSV), among others, and cause vast aquaculture and wildlife problems ([@cwy053C179]). Though the number of potential *N*-glycans varies by virus, a putative *N*-glycan at position N438 is present in each virus analyzed ([@cwy053C134]; [@cwy053C19]). IHNV G contains four potential *N*-glycosylation sites and one potential *O*-glycosylation site ([@cwy053C11]). VHSV also contains four potential *N*-glycosylation sites ([@cwy053C35]), and IHNV and VHSV share similar glycosylation patterns: one putative *N*-glycan at the N-terminus, none in the middle of the protein and three at the C-terminus ([@cwy053C134]). HIRV contains three putative *N*-glycosylation sites---all at the C-terminus ([@cwy053C19]). Studies on the function of these glycans, however, have yet to be undertaken.

### Perhabdovirus {#cwy053s36}

*Perhabdoviruses* are associated with fish infections. The eel virus European X (EVEX) is a major concern with the farming of freshwater eels, *Anguilla* species, with increased mortality and symptoms including hemorrhages in the skin and lesions ([@cwy053C29]). The EVEX G protein has one *N*-glycosylation site at N185 ([@cwy053C66]). Functions of glycans in this genus remain unknown.

### Sigmavirus {#cwy053s37}

Five members of the *Drosophila* genus, and one member of the muscidae are natural hosts of sigma viruses that cause paralysis and death upon exposure to carbon dioxide. Sigma viruses have a vertical mode of transmission through the gametes of male or female flies. Drosophila melanogaster sigmavirus (DMelSV) has a surface GP (G) ([@cwy053C133], [@cwy053C134]). Not much is known regarding the number or function of glycans in this genus.

### Sprivivirus {#cwy053s38}

Viruses within the *Sprivivirus* genus infect fish species, causing significant morbidity and mortality ([@cwy053C179]). These viruses include spring viremia of carp virus (SVCV) and pike fry rhabdovirus (PFRV). Not much is known about glycosylation for these viruses, except that the SVCV G GP contains five potential *N*-glycosylation sites. A variation in the glycosylation site N362 is due to nucleotide insertion differences between SVCV strains ([@cwy053C19]; [@cwy053C260]). Potential function of these glycans for any of these viruses have yet to be studied.

### Sripuvirus {#cwy053s39}

Within the *Sripuvirus* genus, the Almpiwar virus G GP contains two possible glycosylation sites with unknown biological function ([@cwy053C153]). The sandfly Niakha virus G GP is reported to possess two potential *N*-glycosylation sites ([@cwy053C229]).

### Tibrovirus {#cwy053s40}

Tibrovirus is transmitted by *Culicoides* insects and infects members of the bovine species. Tibroviruses have not been observed to induce illness. Both the Tibrogargan virus (TIBV) and the Coastal Plains virus (CPV) G proteins are predicted to contain nine *N*-glycosylation sites ([@cwy053C42]; [@cwy053C81]). No account has been made on the function of glycosylation sites in this genus.

### Tupavirus {#cwy053s41}

The Tupaia virus (TUPV) was first isolated in a liver tumor of a Tupaia tree shrew, *Tupaia belangeri* ([@cwy053C114]). The TUPV G protein possesses three potential *N*-glycosylation sites ([@cwy053C208]). The Durham virus (DURV) was first isolated in 2005 in an American coot suffering from neurological symptoms. The DURV G protein was reported to have two possible *N*-glycosylation sites ([@cwy053C8]). Not much is known regarding the number or function of glycans in this genus.

### Varicosavirus {#cwy053s42}

The sole member of the *Varicosavirus* genus is the lettuce big-vein-associated virus (LBVaV). LBVaV causes pale yellow veins on leaves of lettuce and is characterized by leaf puckering. It is considered to be soil-borne and transmitted by zoospores of the fungus, *Olpidium brassicae*, and healthy lettuce planted into contaminated soil will develop signs of infection ([@cwy053C219]; [@cwy053C223]). LBVaV has a difficult mechanical transmission which makes studying it problematic ([@cwy053C194]). There is no report on the glycobiology of this genus.

### Vesiculovirus {#cwy053s43}

VSV infects mainly livestock, causing severe blistering and/or ulceration of the tongue, mouth and feet, often resulting in extensive productivity loss ([@cwy053C123]). VSV is also used extensively in the production of pseudotyped viruses due to its ability to incorporate viral GPs from many other viral families ([@cwy053C91]; [@cwy053C242]). VSV GP (G) contains two well-conserved *N*-glycosylation sites (N181 and N336), which make up approximately 10% of the GP's mass, and no *O*-glycosylation sites have been discovered ([@cwy053C55], [@cwy053C56]; [@cwy053C187]; [@cwy053C181]; [@cwy053C59]). Tunicamycin treatment, particularly of the San Juan strain, impaired intracellular transport of VSV G to the plasma membrane ([@cwy053C119]; [@cwy053C162]; [@cwy053C74]), inhibited viral replication ([@cwy053C120]) and altered MAb-binding patterns to the VSV G GP ([@cwy053C80]). However, these effects appeared to be partially strain-specific, as tunicamycin treatment of the New Jersey strain slowed the folding rate of VSV G but did not prevent its eventual expression at the cell surface ([@cwy053C152]). Additionally, the Orsay strain showed some resistance to tunicamycin treatment ([@cwy053C74]).

It appears that these observed effects are reliant on the presence of a glycan itself, but the specific types of carbohydrates added are not important. For example, VSV particles produced in a variety of CHO cells lacking specific steps in the glycosylation pathway were still able to replicate and were as infectious as their fully glycosylated counterparts ([@cwy053C197]; [@cwy053C186]). It was also shown that either of the two *N*-glycans was necessary and sufficient for proper G transport, ([@cwy053C137]). This observation is further supported by a naturally occurring mutant containing only one *N*-glycan that trafficked properly to the cell surface ([@cwy053C110]). It was also observed that the addition of new *N*-glycosylation sites to unglycosylated VSV G allowed for transport of G to the plasma membrane, though this restored transport ability was only successful for two of the six engineered *N*-glycosylation sites ([@cwy053C138]).

These findings and experiments with temperature-sensitive mutants have led to the hypothesis that *N*-glycans on VSV G are important for proper folding and conformation ([@cwy053C33]; [@cwy053C139]), perhaps affecting the stability of disulfide bonds ([@cwy053C80]), and altered conformations in the absence of *N*-glycosylation sites results in a lack of transport to the cell surface ([@cwy053C33]; [@cwy053C139]). It has been observed that low amounts of infectious virus are produced even in the presence of tunicamycin and it is possible that some glycan mutant virions with different conformations may thus be able to traffic to the cell surface despite a lack of glycosylation ([@cwy053C73]). This may also explain why certain strains are more resistant to tunicamycin treatment than others, as different amino acid sequences may result in different conformations that are more or less reliant on *N*-glycans for their structural integrity ([@cwy053C33]). Thus, it appears that either of the two natural *N*-glycan is necessary and sufficient for proper VSV G transport and expression, suggesting that proper GP conformation, and not specific *N*-glycans, is most important for VSV G expression and function.

### Summary for *Rhabdoviridae* {#cwy053s44}

The lyssavirus and vesiculovirus genera have two highly conserved *N*-glycans on G, which suggests these sites are evolutionarily important. Indeed, sequence comparisons between RABV G and VSV G show approximately 20% overall sequence identity between these two GPs, yet greater than 50% identity around the most C-terminal *N*-glycosylation site, with exact alignment at the *N*-glycosylation site itself ([@cwy053C190]). For both genera, *N*-glycans appear to be necessary for proper transport to the cell surface, with one *N*-glycan being sufficient for the cell transport function ([@cwy053C137]; [@cwy053C110]; [@cwy053C203]). Additionally, dependence on *N*-glycans for proper trafficking is independent on the type of glycan processing, as evidenced by a variety of glycosylation-deficient CHO cells where the G GP was still expressed at the cell surface ([@cwy053C26]; [@cwy053C197]; [@cwy053C186]). The effects of *N*-glycans appear to be more strain-specific for VSV. Although RABV strains differ more in the number of *N*-glycans present, the effects of tunicamycin treatment appear to be more variable among VSV strains than among RABV strains. General comparisons among the other *Rhabdoviruses* are difficult to make since far fewer studies exist. However, these viruses could potentially contain more *N*-glycosylation sites than their lyssavirus and vesiculovirus counterparts, though studies determining site usage have yet to be undertaken.

Sunviridae {#cwy053s45}
----------

The *Sunviridae* family is solely comprised of the Sunshine Coast virus in the *Sunshinevirus* genus. This virus was initially isolated from Australian python snake populations showing symptoms of neurorespiratory disease and is not known to cause illness in humans ([@cwy053C93]). No studies have been performed on the function of glycans for this virus.

Discussion and conclusions {#cwy053s46}
==========================

Glycosylation is a common protein modification process utilized by animals, plants, bacteria, fungi, viruses and even some archaea, illustrating its importance ([@cwy053C226]). In recent years, many human illnesses, such as autoimmune diseases and cancer, have been linked to altered glycosylation ([@cwy053C225]; [@cwy053C227]). Glycosylation is commonly used by pathogens in host invasion and immune evasion. Within the *Mononegavirales* order there are many conserved functions of glycosylation, such as receptor binding, viral entry, protein processing or trafficking, cell--cell fusion and immunogenicity (Table [I](#cwy053TB1){ref-type="table"}, Figure [3](#cwy053F3){ref-type="fig"}), all important roles for the viral life cycle. It should be noted that much more has been discovered for *N*-glycans than *O*-glycans, partly due to the difficulty in determining *O*-glycosylation sites compared to *N*-glycosylation sites. Few *O*-glycan functions have been described. Many functions have been attributed to *O*-glycan-rich regions, such as that of the Ebola GP, yet these functions have yet to be directly attributed to the *O*-glycans themselves. In a new study for the *Henipavirus* genus, novel roles were shown for NiV and HeV *O*-glycans ([@cwy053C212]). It remains to be seen if such roles apply to other paramyxoviruses or mononegaviruses. Table I.Many glycan functions are conserved among viral genera. Summary of the different functions documented for each viral genera. N = *N*-glycans are involved. O = *O*-glycans are involved. Dashed line = not involved, blan k = not documented, unknown. \# marks functions documented for an *O*-glycan-rich region (but not specifically the *O*-glycans themselves)FamilyGenusReceptor bindingViral entryProcessing and traffickingCell--cell fusionInfectious virion productionImmunogenicity*BornaviridaeBornavirus*N*FiloviridaeCuevavirus*N, \#*Ebolavirus*NN, \#N, \#\#N, \#*MarburgvirusMymonaviridaeSclerotimonavirusNyamiviridaeNyavirusPeropuvirusSocyvirusParamyxoviridaeAquaparamyxovirus*NN*Avulavirus*--NNN*FerlavirusHenipavirus*--N, ON, ON, ON*Morbillivirus*NNNN*Respirovirus*NNNNN*Rubulavirus*NNN*PneumoviridaeMetapneumovirus*NNN*Orthopneumovirus*N*RhabdoviridaeAlmendavirusCuriovirusCytorhabdovirusDichorhavirusEphemerovirusHapavirusLedantevirusLyssavirus*NNN*NovirhabdovirusNucleorhabdovirusPerhabdovirusSigmavirusSprivivirusSripuvirusTibrovirusTupavirusVaricosavirusVesiculovirus*NNN*SunviridaeSunshinevirus*

A more thorough understanding of viral glycosylation has the potential for therapeutic use. Glycomimetics, compounds that mimic the bioactive properties of carbohydrates, are being developed and tested for a number of different viral infections ([@cwy053C52]; [@cwy053C140]). The glucose-mimetic *N*-9-methoxynonyl (DNJ), for example, inhibits a part of the glycosylation pathway, thus preventing viral GPs from folding properly ([@cwy053C64]; [@cwy053C44]). DNJ has been shown to be effective in combating HIV, hepatitis B and C viruses and has been suggested as a possible therapeutic against the flaviviruses dengue virus and West Nile virus ([@cwy053C158]). Carbohydrate mimetics are suggested to be good drug candidates because they generally have a low toxicity, are water soluble, can be easily modified by adding different functional groups at multiple locations and have the potential to be used as scaffolds for more complex drugs ([@cwy053C158]). However, carbohydrates generally have been thought to make poor drug candidates due to their high polarity, preventing passive transport through the intestinal lining (and thus problematic for oral dosing regimens). The use of carbohydrate mimetics enables sufficient manipulation to overcome this barrier ([@cwy053C52]).

The addition of glycans to proteins can also be used as a tool to study protein functions. For example, for the paramyxoviral HN/H/G attachment GPs, *N*-glycans have been added to study the effects of the protein stalk on membrane fusion and interactions with the fusion protein. This has been done for NDV, PIV-5 and NiV to probe protein function ([@cwy053C157]; [@cwy053C23]; [@cwy053C261]).

Lectins and other carbohydrate-binding agents are also being investigated as antiviral therapies ([@cwy053C52]). Cyanovirin is a lectin that binds the gp120 GP of HIV and prevents entry and was tested against many other viruses as well ([@cwy053C158]; [@cwy053C64]). Carbohydrate-binding agents cannot only bind the viral GPs to prevent entry but also can create a long-term selective pressure for viral strains with the protective *N*-glycan regions removed, thus making the virus more susceptible to immune system neutralization ([@cwy053C64]). Lectins are also found naturally across a wide variety of species (prokaryotes, algae, fungi, plants, invertebrates and vertebrates). Thus, there are many different lectins to explore as potential viral inhibitors ([@cwy053C64]). Antibodies against the carbohydrates of viral proteins, though less common, can also be effective. 2G12 is an antibody that binds an *N*-glycan region of gp120 on HIV, thus inhibiting viral entry into host cells and limiting HIV infections ([@cwy053C158]; [@cwy053C64]). Thus, a number of viral glycosylation-targeting therapeutics are in development that have potential to inhibit viral infections. It is also likely that a combination of these strategies will prove best for maximal therapeutic benefit.

While significant advances in understanding and characterizing viral glycosylation have been made, there are still many knowledge gaps. Mass spectrometric data for many viral GPs is still nonexistent, particularly for *O*-glycans. Some of the methods commonly used to study glycosylation effects, such as tunicamycin treatment, may cause additional cellular effects, thus any effects observed after tunicamycin treatment may be from the treatment itself and not directly from a lack of glycosylation. A significant hurdle to overcome is that there is considerable variation in glycosylation machinery among different cell types; therefore, the effects of glycosylation observed in one study may not hold true in other cell types or in vivo. Nevertheless, the advances made in recent years and the knowledge gained continues to highlight how crucial proper glycosylation of viral GPs is for their function and for viral pathogenicity. Improved understanding of viral glycosylation is essential to pave the way for future therapeutics and vaccines targeting important medical, agricultural and veterinary viruses.
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ABTV

:   Arboretum virus

APMV-1

:   avian paramyxovirus

AsaPV

:   Atlantic salmon paramyxovirus

BALV

:   Balsa virus

BEFV

:   bovine ephemeral fever virus

CBV

:   Coot Bay virus

CDV

:   canine distemper virus

CoRSV

:   coffee ringspot virus

CPV

:   Coastal Plains virus

CSE

:   cell surface expression

DMelSV

:   Drosophila melanogaster sigmavirus

DURV

:   Durham virus

EBOV

:   Ebola virus

ER

:   endoplasmic reticulum

EVEX

:   eel virus European X

FDLV

:   Fer-de-Lance virus

GP

:   glycoprotein

HeV

:   Hendra virus

HIRV

:   hirame rhabdovirus

HIV

:   human immunodeficiency virus

HMPV

:   human metapneumovirus

HPIV

:   human parainfluenza virus

HRSV

:   human respiratory syncytial virus

IHNV

:   infectious hematopoietic necrosis virus

LBVaV

:   lettuce big-vein-associated virus

LLOV

:   Lloviu virus

LNYV

:   lettuce necrotic yellow virus

Mev

:   measles virus

MIDWV

:   Midway virus

MLD

:   mucin-like domain

MuV

:   mumps virus

NCMV

:   Northern cereal mosaic virus

NGAV G

:   Ngaingan virus

NiV

:   Nipah virus

NYMV

:   Nyamanini virus

OFV

:   orchid fleck virus

PFRV

:   pike fry rhabdovirus

PIV

:   parainfluenza viruses

PIV-5

:   parainfluenza virus 5

PNGase F

:   peptide-*N*-glycosidase F

PpNSRV-1

:   Pteromalus puparum negative-strand RNA virus 1

PTAMV

:   Puerto Almendras virus

RABV

:   rabies virus

RCHV

:   Rio Chico virus

RYSV

:   rice yellow stunt virus

SbCNV

:   soybean cyst nematode virus-1

SeV

:   Sendai virus

SLAM

:   signaling lymphocyte activation molecule

SNVV

:   Sierra Nevada virus

SsNSRV-1

:   Sclerotinia sclerotiorum negative-stranded RNA virus 1

SVCV

:   spring viremia of carp virus

SYNV

:   sonchus yellow net virus

TIBV

:   Tibrogargan virus

TUPV

:   Tupaia virus

VHSV

:   viral hemorrhagic septicemia virus

VLPs

:   virus-like particles

VSV

:   vesicular stomatitis virus.

[^1]: Victoria Ortega and Jacquelyn A Stone contributed equally.
